<p>Supplemental Table S1</p><p>To accompany ‘Neonatal and infant outcome in boys and girls born very prematurely’</p><p>Janet L Peacock, Louise Marston, Neil Marlow, Sandy A Calvert, Anne Greenough Table S1 24 month follow-up outcomes (Maximum n=366)</p><p>Outcome Male Female Difference Adjusted difference* Adjusted difference** Adjusted difference† a) Neurological outcomes</p><p>Unable to sit 3% 1% 1% (-2%, 5%) 1% (-2%, 5%) 2% (-2%, 5%) 0% (-2%, 3%)</p><p>Unable to stand 8% 6% 2% (-3%, 8%) 2% (-4%, 7%) 2% (-4%, 7%) 1% (-5%, 6%)</p><p>Unable to walk 14% 7% 6% (0%, 13%) 6% (-1%, 12%) 6% (-1%, 12%) 2% (-4%, 8%)</p><p>Unable to use left hand 6% 4% 2% (-3%, 7%) 2% (-3%, 7%) 2% (-3%, 7%) 0% (-5%, 5%)</p><p>Unable to use right hand 5% 2% 3% (-1%, 7%) 3% (-1%, 7%) 3% (-1%, 7%) 2% (-3%, 6%)</p><p>Unable to perform bimanual tasks 6% 6% 1% (-5%, 6%) 0% (-5%, 6%) 0% (-5%, 6%) 2% (-4%, 7%)</p><p>Seizures 4% 7% -3% (-9%, 2%) -4% (-9%, 2%) -3% (-9%, 2%) -4% (-10%, 3%)</p><p>Vision problems 6% 5% 1% (-4%, 6%) 1% (-4%, 6%) 1% (-4%, 6%) -0% (-6%, 5%)</p><p>Squint 14% 10% 4% (-3%, 11%) 4% (-3%, 11%) 4% (-3%, 11%) 0% (-8%, 8%)</p><p>Eye movements 4% 5% -1% (-6%, 3%) -1% (-6%, 3%) -1% (-6%, 3%) -2% (-7%, 4%)</p><p>Hearing loss 10% 4% 7% (1%, 12%) 6% (1%, 12%) 7% (1%, 12%) 7% (1%, 13%)</p><p>Feeding problems 2% 1% 0% (-3%, 3%) 0% (-3%, 3%) 0% (-3%, 3%) -0% (-3%, 3%)</p><p>Any disability‡ 53% 39% 14% (3%, 24%) 15% (4%, 25%) 15% (3%, 27%) 12% (-1%, 25%)</p><p>Cognitive delay§ 35% 19% 15% (4%, 26%) 17% (6%, 28%) 14% (2%, 26%) 8% (-4%, 22%) b) Respiratory outcomes</p><p>Cough 52% 47% 5% (-6%, 16%) 7% (-4%, 18%) 6% (-5%, 17%) 7% (-4%, 18%)</p><p>In those with cough:</p><p>Frequent cough 30% 30% 0% (-14%, 14%) 1% (-13%, 15%) 2% (-13%, 16%) -2% (-16%, 13%)</p><p>Cough with exercise 33% 29% 5% (-12%, 21%) 6% (-11%, 23%) 3% (-14%, 20%) 4% (-12%, 21%)</p><p>Cough without infection 89% 84% 5% (-5%, 15%) 5% (-6%, 16%) 6% (-5%, 17%) 6% (-5%, 17%)</p><p>Wheeze 41% 33% 8% (-2%, 19%) 9% (-2%, 19%) 9% (-2%, 19%) 9% (-2%, 20%)</p><p>In those with wheeze:</p><p>Wheeze with exercise 43% 31% 12% (-8%, 32%) 14% (-6%, 34%) 9% (-12%, 30%) 10% (-11%, 31%)</p><p>Wheeze without infection 92% 87% 6% (-6%, 18%) 5% (-6%, 16%) 4% (-7%, 15%) 4% (-7%, 15%)</p><p>Any chest medicines 62% 52% 10% (-1%, 20%) 11% (-0%, 21%) 10% (-1%, 21%) 12% (0%, 23%)</p><p>Bronchodilators 47% 31% 16% (6%, 26%) 18% (8%, 29%) 17% (7%, 28%) 18% (7%, 29%)</p><p>Inhaled steroids 30% 16% 14% (5%, 22%) 16% (7%, 24%) 14% (5%, 22%) 14% (5%, 23%)</p><p>Bronchodilators or inhaled steroids 48% 31% 18% (7%, 28%) 20% (10%, 31%) 19% (8%, 29%) 20% (9%, 30%)</p><p>Footnotes * adjusted for birthweight and GA and adjusted for clustering in multiple births (19) ** adjusted for birthweight, GA and O2 dependence at 36 weeks and major cranial abnormality (any disability and cognitive delay), and adjusted for clustering in multiple births (19) † adjusted for birthweight, GA, O2 dependence at 36 weeks, major cranial abnormality (any disability and cognitive delay), length of hospital stay after birth, age at 24 month assessment and weight standard deviation score (SDS) at 24 months. respiratory outcomes: adjusted for birthweight, GA, O2 dependence at 36 weeks, multiple birth and older sibling aged<5. All analyses adjusted for clustering in multiple births (19) ‡ Any disability is derived from paediatrician report as detailed in Marlow (16) § Cognitive delay assessed by Parent Report of Children’s Abilities (PARCA) score <49 that corresponds to Mental Development Index (MDI) ≤ 70 (Johnson 2004, (18))</p><p>Results in BOLD indicate P<0.05 </p>